Unique ID issued by UMIN | UMIN000001413 |
---|---|
Receipt number | R000001716 |
Scientific Title | Phase 2 study of induction and early consolidation therapy for acute lymphoblastic leukemia in children (TCCSG ALL L04-16). |
Date of disclosure of the study information | 2008/10/05 |
Last modified on | 2010/10/30 14:29:03 |
Phase 2 study of induction and early consolidation therapy for acute lymphoblastic leukemia in children (TCCSG ALL L04-16).
Phase 2 study of induction and early consolidation therapy for ALL in children (TCCSG ALL L04-16).
Phase 2 study of induction and early consolidation therapy for acute lymphoblastic leukemia in children (TCCSG ALL L04-16).
Phase 2 study of induction and early consolidation therapy for ALL in children (TCCSG ALL L04-16).
Japan |
Acute Lymphoblastic Leukemia
Hematology and clinical oncology | Pediatrics |
Malignancy
NO
The purpose of this study is to investigate efficacy and safety for treating pediatric ALL with conventional induction and early consolidation therapy.
Safety,Efficacy
Pragmatic
Phase II
The rate of complete remission at the completion of early consolidation.
1.The complete remission induction rate
2.The frequency of therapy toxicity
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
For standard and intermediate risk patients;
Induction therapy-A (Week 1-6): PSL, VCR, THP-ADR, L-ASP, MTX, Ara-C, HDC.
Consolidation therapy-A for standard and intermediate risk patients (Week 8-10): 6MP, Ara-C, CPM, MTX, HDC.
For high risk patients;
Induction therapy-B (Week 1-6): PSL, VCR, THP-ADR,DNR, CPA, L-ASP, MTX, Ara-C, HDC.
Early Consolidation therapy-B (Week 8): DEX, MTX, CPA, Ara-C, L-ASP, HDC.
1 | years-old | <= |
18 | years-old | > |
Male and Female
(1) Previously untreated ALL,
(2) Age between 1 and 18 years,
(3) Karnofsky Performance status score >50,
(5) Written informed consent to participate the trial.
(1)Symptomatic intracranial hemorrhage
(2) Uncontroled infection,
(3) Double cancer, Secondary leukemia,
(4) Down syndrome,
(5) Pregnant, lactating woman,
(6) Inadequate functioning of the liver (ALT>200 and serum total bilirubin level > 1.5 mg/dL), kidneys (serum creatinine level >= 1.5 mg/dL),
(7) cardiac dysfunction, pulmonary dysfunction
300
1st name | |
Middle name | |
Last name | Akira Ohara |
Toho University
Omori Hospital, Dep.of Transfusion
6-11-1, Omori-Nishi, Ota-ku, Tokyo
03-3762-4151
1st name | |
Middle name | |
Last name | Akira Ohara |
Toho University
Omori Hospital, Dep.of Transfusion
6-11-1, Omori-Nishi, Ota-ku, Tokyo
03-3762-4151
aohara@med.toho-u.ac.jp
Tokyo Children's Cancer Study Group
1.Ministry of Health, Labor and Welfare, "Study on establishment of the multicenter clinical study for standard therapy to pediatric sarcoma"
2.Children's Cancer Association of Japan
Japan
NO
2008 | Year | 10 | Month | 05 | Day |
Partially published
Interim analysis of the 150 patients. Complete remission rate at completion of early consolidation is estimated as 97%. No unexpected treatment toxicity was reported.
Completed
2004 | Year | 11 | Month | 25 | Day |
2004 | Year | 12 | Month | 01 | Day |
2010 | Year | 07 | Month | 01 | Day |
2010 | Year | 08 | Month | 01 | Day |
2010 | Year | 10 | Month | 01 | Day |
2010 | Year | 12 | Month | 01 | Day |
2008 | Year | 10 | Month | 02 | Day |
2010 | Year | 10 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001716
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |